Post-acute sequelae of COVID-19 in a non-hospitalized cohort: results from the Arizona CoVHORT
| Autor: | Yann C. Klimentidis, Kristen Pogreba-Brown, Elizabeth T. Jacobs, Megan Jehn, Leslie V. Farland, Collin J. Catalfamo, Melanie L. Bell, Kacey C. Ernst |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
RNA viruses
Male Viral Diseases Pulmonology Coronaviruses Disease Surveys 01 natural sciences Geographical locations Cohort Studies Medical Conditions 0302 clinical medicine Allergies Medicine and Health Sciences Prevalence Medicine 030212 general & internal medicine Young adult Child Pathology and laboratory medicine Fatigue Virus Testing Aged 80 and over Multidisciplinary Arizona Medical microbiology Middle Aged Prognosis Home Care Services Infectious Diseases Research Design Viruses Cohort Disease Progression Anxiety Female SARS CoV 2 Pathogens medicine.symptom Research Article Cohort study Adult Moderate to severe medicine.medical_specialty 2019-20 coronavirus outbreak SARS coronavirus Adolescent Coronavirus disease 2019 (COVID-19) Science Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Research and Analysis Methods Microbiology Respiratory Disorders Young Adult 03 medical and health sciences Signs and Symptoms Post-Acute COVID-19 Syndrome Diagnostic Medicine Internal medicine Humans 0101 mathematics Aged Survey Research Biology and life sciences SARS-CoV-2 business.industry 010102 general mathematics Organisms Viral pathogens COVID-19 Covid 19 United States Confidence interval Microbial pathogens Dyspnea Diverse population El Niño North America Clinical Immunology Clinical Medicine People and places business |
| Zdroj: | PLoS ONE, Vol 16, Iss 8, p e0254347 (2021) PLoS ONE, Vol 16, Iss 8 (2021) PLoS ONE |
| DOI: | 10.1101/2021.03.29.21254588 |
| Popis: | Clinical presentation, outcomes, and duration of COVID-19 has ranged dramatically. While some individuals recover quickly, others suffer from persistent symptoms, collectively known as long COVID, or post-acute sequelae of SARS-CoV-2 (PASC). Most PASC research has focused on hospitalized COVID-19 patients with moderate to severe disease. We used data from a diverse population-based cohort of Arizonans to estimate prevalence of PASC, defined as experiencing at least one symptom 30 days or longer, and prevalence of individual symptoms. There were 303 non-hospitalized individuals with a positive lab-confirmed COVID-19 test who were followed for a median of 61 days (range 30–250). COVID-19 positive participants were mostly female (70%), non-Hispanic white (68%), and on average 44 years old. Prevalence of PASC at 30 days post-infection was 68.7% (95% confidence interval: 63.4, 73.9). The most common symptoms were fatigue (37.5%), shortness-of-breath (37.5%), brain fog (30.8%), and stress/anxiety (30.8%). The median number of symptoms was 3 (range 1–20). Amongst 157 participants with longer follow-up (≥60 days), PASC prevalence was 77.1%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|